Amemori Takashi, Ruzicka Jiri, Romanyuk Nataliya, Jhanwar-Uniyal Meena, Sykova Eva, Jendelova Pavla
Department of Neuroscience, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Videnska 1083, 142 20, Prague 4, Czech Republic.
Department of Neuroscience, 2nd Faculty of Medicine, Charles University, Plzenska 130/221, 150 00, Prague 5, Czech Republic.
Stem Cell Res Ther. 2015 Dec 22;6:257. doi: 10.1186/s13287-015-0255-2.
Stem cell treatment provides a promising therapy for patients with spinal cord injury (SCI). However, the applied stem cells exert their effects in different manners that are dependent on the route used for administration.
In the present study, we administered neural precursors derived from induced pluripotent stem cells (iPS-NPs) either intraspinally into the lesion center or intrathecally into the subarachnoid space of rats with a balloon-induced spinal cord compression lesion. Functional locomotor performance, cell survival, astrogliosis, axonal sprouting and the expression of endogenous neurotrophic growth factors were evaluated using behavioral tests (BBB, flat beam test, rotarod, plantar test), morphometric analysis, immunohistochemistry and qPCR.
Both treatments facilitated the functional locomotor recovery of rats with SCI. iPS-NPs injected intraspinally survived well for 2 months and were positive for MAP2, while cells grafted intrathecally were undetectable at the site of administration or in the spinal cord tissue. Intraspinal implantation increased gray and white matter sparing and axonal sprouting and reduced astrogliosis, while intrathecal application resulted only in an improvement of white matter sparing and an increase in axonal sprouting, in parallel with no positive effect on the expression of endogenous neurotrophic growth factor genes or glial scar reduction.
Intrathecally grafted iPS-NPs had a moderate therapeutic benefit on SCI through a paracrine mechanism that does not require the cells to be present in the tissue; however, the extended survival of i.s. grafted cells in the spinal cord may promote long-term spinal cord tissue regeneration.
干细胞治疗为脊髓损伤(SCI)患者提供了一种有前景的治疗方法。然而,所应用的干细胞以不同方式发挥作用,这取决于给药途径。
在本研究中,我们将诱导多能干细胞来源的神经前体细胞(iPS-NPs)经脊髓内注入损伤中心或经鞘内注入患有球囊诱导脊髓压迫性损伤大鼠的蛛网膜下腔。使用行为测试(BBB、平板光束测试、转棒试验、足底测试)、形态计量分析、免疫组织化学和定量聚合酶链反应评估功能运动性能、细胞存活、星形胶质细胞增生、轴突芽生和内源性神经营养生长因子的表达。
两种治疗均促进了SCI大鼠的功能运动恢复。经脊髓内注射的iPS-NPs存活良好达2个月且MAP2呈阳性,而经鞘内移植的细胞在给药部位或脊髓组织中未检测到。脊髓内植入增加了灰质和白质保留以及轴突芽生,并减少了星形胶质细胞增生,而鞘内应用仅导致白质保留改善和轴突芽生增加,同时对内源性神经营养生长因子基因的表达或胶质瘢痕减少没有积极影响。
经鞘内移植的iPS-NPs通过旁分泌机制对SCI有适度的治疗益处,该机制不需要细胞存在于组织中;然而,脊髓内移植细胞的长期存活可能促进脊髓组织的长期再生。